{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:59:54Z","timestamp":1793735994521,"version":"4.6.1"},"reference-count":35,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Natural Youth Science Foundation Project","award":["82001324"],"award-info":[{"award-number":["82001324"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,11,28]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glibenclamide has garnered attention due to its multifaceted neuroprotective effects in cases of acute central nervous system injury. We initiated a trial to explore the effectiveness and safety of a high dose of glibenclamide in the management of cerebral oedema following aneurysmal subarachnoid haemorrhage (aSAH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This trial constituted a single-centre, randomised clinical study. Half of the 56 patients assigned to the glibenclamide group received 15\u2009mg of glibenclamide tablets daily for 10 days (5\u2009mg, three times\/day). The primary outcome was the proportion of patients achieving the subarachnoid haemorrhage early brain oedema score dichotomy (defined as Subarachnoid Haemorrhage Early Brain Oedema Score 0\u20132) at the 10-day postmedication. The secondary outcome of cerebral oedema was the concentration of sulfonylurea receptor 1-transient receptor potential melastatin 4 (SUR1-TRPM4) in the plasma and cerebrospinal fluid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 56 patients diagnosed with aSAH, who were admitted to the neurosurgery intensive care unit between 22 August 2021 and 25 April 2023. The primary outcome revealed that the glibenclamide group exhibited a notably higher proportion of mild cerebral oedema in comparison to the placebo group (60.7% vs 42.9%, adjusted OR: 4.66, 95%\u2009CI 1.14 to 19.10, p=0.032). Furthermore, the concentration of SUR1-TRPM4 in the cerebrospinal fluid of the glibenclamide group was significantly higher than the placebo group (p=0.0002; p=0.026), while the plasma TRPM4 concentration in the glibenclamide group was significantly lower than the placebo group (p=0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Oral administration of high-dose glibenclamide notably reduced radiological assessment of cerebral oedema after 10 days of medication. Significant alterations were also observed in the concentration of SUR1-TRPM4 in plasma and cerebrospinal fluid. However, it is worth noting that glibenclamide was associated with a higher incidence of hypoglycaemia. Larger trials are warranted to evaluate the potential benefits of glibenclamide in mitigating swelling and then improving neurological function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>ChiCTR2100049908.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/svn-2023-002892","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:57:45Z","timestamp":1704848265000},"page":"530-540","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial"],"prefix":"10.1136","volume":"9","author":[{"given":"Xuebing","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-6828","authenticated-orcid":false,"given":"Hongqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-7695","authenticated-orcid":false,"given":"Yueqiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"2025081709301173000_9.5.530.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308413"},{"key":"2025081709301173000_9.5.530.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30668-7"},{"key":"2025081709301173000_9.5.530.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.117655"},{"key":"2025081709301173000_9.5.530.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2009.10.002"},{"key":"2025081709301173000_9.5.530.5","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e3182587839"},{"key":"2025081709301173000_9.5.530.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-015-1036-0","article-title":"Subarachnoid hemorrhage: who dies, and why?","volume":"19","author":"Lantigua","year":"2015","journal-title":"Crit Care"},{"key":"2025081709301173000_9.5.530.7","doi-asserted-by":"publisher","DOI":"10.1161\/hs0102.101080"},{"key":"2025081709301173000_9.5.530.8","doi-asserted-by":"crossref","first-page":"106252","DOI":"10.1016\/j.clineuro.2020.106252","article-title":"Decompressive craniectomy in aneurysmal subarachnoid hemorrhage: who and when? - A systematic review and meta-analysis","volume":"199","author":"Darkwah Oppong","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"2025081709301173000_9.5.530.9","doi-asserted-by":"publisher","DOI":"10.3171\/2016.9.Jns161383"},{"key":"2025081709301173000_9.5.530.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6674.636"},{"key":"2025081709301173000_9.5.530.11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.572644"},{"key":"2025081709301173000_9.5.530.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32041"},{"key":"2025081709301173000_9.5.530.13","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2009.1021"},{"key":"2025081709301173000_9.5.530.14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1593\/neo.13164","article-title":"Inhibition of sur1 decreases the vascular permeability of cerebral metastases","volume":"15","author":"Thompson","year":"2013","journal-title":"Neoplasia"},{"key":"2025081709301173000_9.5.530.15","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2008.120"},{"key":"2025081709301173000_9.5.530.16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.23736\/S0390-5616.22.05271-7","article-title":"Glibenclamide reduces secondary brain injury in a SAH rat model by reducing brain swelling and Modulating inflammatory response","volume":"67","author":"Kajimoto","year":"2023","journal-title":"J Neurosurg Sci"},{"key":"2025081709301173000_9.5.530.17","doi-asserted-by":"crossref","unstructured":"Costa B da , Windlin IC , Koterba E , et al . Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial. J Neurosurg 2021:1\u20138. doi:10.3171\/2021.7.JNS21846","DOI":"10.3171\/2021.7.JNS21846"},{"key":"2025081709301173000_9.5.530.18","first-page":"126","article-title":"Expert consensus on the management of severe aneurysmal subarachnoid hemorrhage 2023","volume":"20","author":"Xu","year":"2023","journal-title":"Chinese Journal of Cerebrovascular Disease"},{"key":"2025081709301173000_9.5.530.19","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000015624.29071.1F"},{"key":"2025081709301173000_9.5.530.20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ane.13134","article-title":"Exploratory analysis of oral glibenclamide in acute ischemic stroke","volume":"140","author":"Huang","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"2025081709301173000_9.5.530.21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12028-016-0354-7","article-title":"Mechanisms of global cerebral edema formation in aneurysmal subarachnoid hemorrhage","volume":"26","author":"Hayman","year":"2017","journal-title":"Neurocrit Care"},{"key":"2025081709301173000_9.5.530.22","doi-asserted-by":"publisher","DOI":"10.1038\/nm1390"},{"key":"2025081709301173000_9.5.530.23","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.522409"},{"key":"2025081709301173000_9.5.530.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30196-X"},{"key":"2025081709301173000_9.5.530.25","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002904"},{"key":"2025081709301173000_9.5.530.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101666","article-title":"Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (gate-ICH): a multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial","volume":"53","author":"Zhao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025081709301173000_9.5.530.27","doi-asserted-by":"crossref","DOI":"10.5812\/traumamon.25113","article-title":"Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma","volume":"21","author":"Zafardoost","year":"2016","journal-title":"Trauma Mon"},{"key":"2025081709301173000_9.5.530.28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.wneu.2017.01.103","article-title":"Effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries: a randomized double-blind placebo-controlled clinical trial","volume":"101","author":"Khalili","year":"2017","journal-title":"World Neurosurgery"},{"key":"2025081709301173000_9.5.530.29","first-page":"141","article-title":"Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects","volume":"8","author":"Rambiritch","year":"2016","journal-title":"Clin Pharmacol"},{"key":"2025081709301173000_9.5.530.30","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000218821.34014.1B"},{"key":"2025081709301173000_9.5.530.31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jns.2017.08.3252","article-title":"Sulfonylurea drug pretreatment and functional outcome in diabetic patients with acute intracerebral hemorrhage","volume":"381","author":"Chang","year":"2017","journal-title":"J Neurol Sci"},{"key":"2025081709301173000_9.5.530.32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16034973"},{"key":"2025081709301173000_9.5.530.33","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X15617172"},{"key":"2025081709301173000_9.5.530.34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.097501"},{"key":"2025081709301173000_9.5.530.35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0271678X211045748","article-title":"A new perspective on cerebrospinal fluid dynamics after subarachnoid hemorrhage: from normal physiology to pathophysiological changes","volume":"42","author":"Fang","year":"2022","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2023-002892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:30:20Z","timestamp":1755448220000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2023-002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,5]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/svn-2023-002892"],"URL":"https:\/\/doi.org\/10.1136\/svn-2023-002892","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}